Yahoo Finance • 7 months ago

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with can... Full story

Yahoo Finance • 7 months ago

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with can... Full story

Yahoo Finance • 10 months ago

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facili... Full story

Yahoo Finance • a year ago

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023... Full story

Yahoo Finance • a year ago

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE)... Full story

Yahoo Finance • a year ago

Here’s Why Instil Bio (TIL) Declined in Q4

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund returned 7.41% net compared to a 4... Full story

Yahoo Finance • a year ago

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL™ to its operations in Manche... Full story

Yahoo Finance • a year ago

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company... Full story

Yahoo Finance • a year ago

INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) on beh... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating PROG, Fox, Instil, and Twist and Encourages Investors to Contact the Firm

NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PROG Holdings, Inc. (NYSE: PRG), Fox Corporation (NASDAQ: FOX, FOXA),... Full story

Mentioned:

• PRG
• TWST

Yahoo Finance • 2 years ago

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell carcinoma Reducing U.... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Fox, Instil, Veru, and Twist and Encourages Investors to Contact the Firm

NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Instil Bio, Inc. (NASDAQ: TIL),... Full story

Mentioned:

• TWST
• VERU

Yahoo Finance • 2 years ago

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Establishment, Accelerate Diagnostics, Instil and Unisys and Encourages Investors to Contact the Firm

NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Establishment Labs Holdings Inc. (NASDAQ: ESTA), Accelerate Diagnosti... Full story

Mentioned:

• AXDX
• ESTA
• UIS

Yahoo Finance • 2 years ago

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with can... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Instil and Encourages Investors to Contact the Firm

NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (NASDAQ: AXDX), and Instil Bio, Inc. (NA... Full story

Mentioned:

• AXDX

Yahoo Finance • 2 years ago

Instil Bio, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 03, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Instil Bio, Inc. (“Instill Bio”) (NASDAQ: TIL) investors that the law... Full story

Yahoo Finance • 2 years ago

TIL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation – TIL

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Instil Bio, Inc. (NASDAQ: TIL) resulting from all... Full story

Yahoo Finance • 2 years ago

Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in their Instil Bio, Inc. investment should contact the firm... Full story

Yahoo Finance • 2 years ago

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actions No regulatory agency, including the FDA, has notified the Company of a clinical hold in any of... Full story